血清血管内皮生长因子/内皮抑素比值与儿童急性白血病的相关性

摘要
图/表
参考文献(18)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (911 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：检测急性白血病（AL）患儿血清血管内皮生长因子（VEGF）、内皮抑素（ES）水平，探讨VEGF /ES (V/E) 比值与儿童AL的临床相关性。方法：采用酶联免疫双抗体夹心法检测35例AL患儿化疗前后血清VEGF、ES水平及V/E比值，并与30例健康儿童进行比较。结果：化疗前AL患儿血清中VEGF和ES水平分别为196±66 pg/mL和 31±7 ng/mL，显著高于对照组（29±10 pg/mL、19±4 ng/mL; P0.05）。35例AL患儿化疗前血清VEGF、V/E 比值与骨髓白血病细胞数呈正相关 (r=0.301和0.411，P<0.05)。结论：血清VEGF和ES与儿童AL的发生发展有关，V/E比值能更准确反映AL患儿疾病动态变化情况，有利于指导相关治疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	顾教伟
	胡忠栋
	刘壮

关键词 ：急性白血病, 血管内皮生长因子/内皮抑素比值, 儿童

Abstract：OBJECTIVE: To investigate the correlation between the ratio of serum vascular endothelial growth factor (VEGF)/endostatin (ES) and childhood acute leukemia(AL). METHODS: Serum levels of VEGF and ES were measured using ELISA in 35 children with acute AL before and after chemotherapy. The ratio of VEGF/ES was calculated. Thirty healthy children served as the control group. RESULTS: The serum levels of VEGF (196±66 pg/mL vs 29±10 pg/mL) and ES (35±7 ng/mL vs 19±4 ng/mL) in the AL group before chemotherapy were significantly higher than those in the control group (P<0.01). The ratio of VEGF/ES in the AL group before chemotherapy was significantly higher than that in the control group (6.7±3.0 vs 1.6±0.7; P<0.01). In 20 children with AL who achieved complete remission, the serum levels of VEGF and ES and the VEGF/ES ratio were reduced after chemotherapy (83±35 pg/mL, 27±5 ng/mL, 3.1±1.3, respectively; P<0.01), although the serum levels of VEGF and ES were still higher than those in the control group (P<0.01). The VEGF/ES ratio in CR patients was not significantly different from that in the control group. The serum levels of VEGF (r=0.301, P=0.045) and the VEGF/ES ratio (r=0.411, P=0.015) were positively correlated with the count of blast cells in juvenile bone marrow in 35 children with AL before chemotherapy. CONCLUSIONS: Serum VEGF and ES levels are associated with the development of childhood AL. The VEGF/ES ratio can be used to evaluate the disease progression in children with AL.

Key words： Acute leukemia Ratio of vascular endothelial growth factor/endostatin Child

PACS:

R733

引用本文:

顾教伟,胡忠栋,刘壮. 血清血管内皮生长因子/内皮抑素比值与儿童急性白血病的相关性[J]. 中国当代儿科杂志, 2011, 13(6): 475-477.

GU Jiao-Wei,HU Zhong-Dong,LIU Zhuang. Correlation between the ratio of serum vascular endothelial growth factor/endostatin and childhood acute leukemia[J]. CJCP, 2011, 13(6): 475-477.

链接本文:

http://www.zgddek.com/CN/ 或 http://www.zgddek.com/CN/Y2011/V13/I6/475

	［1］胡亚美,江载芳．诸福棠实用儿科学［M］．第7版.北京∶人民卫生出版社,2002,2199.
	［2］沈晓明,王卫平．儿科学［M］．第7版.北京：人民卫生出版社,2009：375．
	［3］Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemia and myelodysplastic syndrome［J］. Blood, 2000, 96(6): 2240-2245.
	［4］中华医学会儿科学分会血液学组.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)［J］. 中华儿科杂志，2006, 44(5): 392-395.
	［5］中华医学会儿科学分会血液学组.儿童急性髓细胞白血病诊疗建议［J］. 中华儿科杂志, 2006, 44(11): 877-878.
	［6］Folkman J. Tumor angiogenesis: therapeutic implications［J］. N Engl J Med, 1971, 285(16): 1182-1186.
	［7］Folkman J.Role of angiogenesis in tumor growth and metastasis ［J］. Semin Oncol, 2002, 29(6): 15-18.
	［8］Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia ［J］. Am J Pathol, 1997, 150 (3): 815-821.
	［9］Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes［J］. Blood, 2001, 97(5): 1427-1434.
	［10］Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, et al. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antiboby directed against vascular endothelial growth factor receptor-2［J］. Leuk Lymphoma, 2004, 45(9): 1887-1897.
	［11］Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myloid leukemia［J］. Blood, 1997, 89(6): 1870-1875.
	［12］Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis［J］.J Biol Chem, 1999, 274(17): 11721-11726.
	［13］Chavakis E, Dimrneler S. Regulation of endothelial cell survival and apoptosis during angiogenesis［J］. Arterioscler Thromb Vasc Biol, 2002, 22(6):887-893.
	［14］Chang Z, Choon A, Friedl A. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growh factor-2 binding［J］. Am J Pathol, 1999, 155(1):71-76.
	［15］Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, et al. Endostatin induced tyrosine kinase signaling Through the Shb adaptor protein regulates endothelial cell apoptosis［J］. Blood, 2000, 95(11): 3403-3411.
	［16］Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, et al. Endostatin inhibits the vascular endothelial growth factor induced mobilization of endothelial progenitor cells［J］. Cancer Research, 2003, 63(12): 8345-8350.
	［17］Iversen PO, Sorensen DR, Benestad HB. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias［J］. Leukemia, 2002, 16(3): 376-381.
	［18］Aref S, El-Sherbiny M, Azmy E, Goda T, Selim T, El-Refaie M, et al. Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia［J］. Hematology, 2008, 13(2): 95-100.